Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis

What is the purpose of this trial?

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) as a corticosteroid (CS)-sparing agent in subjects with CS-dependent Myasthenia Gravis (MG).

Participation Guidelines

Ages: 18 - 85 years

Gender: Both

Grifols Worldwide Operations (formerly Grifols Therapeutics)

Start Date: 10/08/2015

End Date: 01/31/2017

Last Updated: 02/22/2018

Study HIC#: 1509016449

Get Involved

For more information about this study, contact:
Joan Nye
+1 203-737-6886

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Richard Nowak

Principal Investigator